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ABSTRACT
The t(8;21) (q22;q22) chromosomal translocation is one of the most frequent 
genetic alterations in acute myeloid leukemia (AML) which has a need for improved 
therapeutic strategies. We found PLC-γ1 as one of the highest phosphorylated 
peptides in t(8;21) AML samples compared to NBM or CN-AML in our previous peptide 
microarray. PLC-γ1 is known to play a role in cancer progression, however, the impact 
of PLC-γ1 in AML is currently unknown. Therefore, we aimed to study the functional 
role of PLC-γ1 by investigating the cellular growth, survival and its underlying 
mechanism in t(8;21) AML.
In this study, PLC-γ1 expression was significantly higher in t(8;21) AML compared 
to other karyotypes. The PLC-γ1 protein expression was suppressed in AML1-ETO knock 
down cells indicating that it might induce kasumi-1 cell death. ShRNA-mediated PLC-γ1 
knockdown in kasumi-1 cells significantly blocked cell growth, induced apoptosis 
and cell cycle arrest which was explained by the increased activation of apoptotic 
related and cell cycle regulatory protein expressions. Gene expression array analysis 
showed the up-regulation of apoptotic and DNA damage response genes together 
with the downregulation of cell growth, proliferation and differentiation genes in the 
PLC-γ1 suppressed kasumi-1 cells, consistent with the observed phenotypic effects. 
Importantly, PLC-γ1 suppressed kasumi-1 cells showed higher chemosensitivity to the 
chemotherapeutic drug treatments and lower cell proliferation upon hypoxic stress.
Taken together, these in vitro finding strongly support an important role for 
PLC-γ1 in the survival of t(8;21) AML mimicking kasumi-1 cells and identify PLC-γ1 
as a potential therapeutic target for t(8;21) AML treatment.
INTRODUCTION
Acute myeloid leukemia (AML) forms a spectrum 
of diseases that share clinical and pathological features, 
which arise from a wide diversity of abnormalities, 
including mutations, cytogenetic abnormalities, 
and epigenetic changes [1–4]. The t(8;21)(q22;q22) 
rearrangement considers the most common chromosomal 
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translocation in AML and consists of a transcript encoding 
for the fusion protein AML1-ETO (A-E or RUNX1-
RUNX1T1) [5]. AML1–ETO is a critical step for the 
pathogenesis of this type of myeloid leukemia, however, 
it requires one or more additional mutations to cause 
leukemia [6–9]. The role of AML1–ETO in the t(8;21) 
translocation positive AML was previously studied and it 
appeared as a promising target, although the effectiveness 
of this therapy remains unclear [10–12]. Patients 
diagnosed with t(8;21) AML undergo conventional 
intensive chemotherapy and have a relatively favorable 
prognosis compared with other types of AMLs [13]. 
Despite the great clinical improvements that have been 
made in the treatment of AML, t(8;21) AML remains a 
significant clinical problem for both children and adults. 
The relapse rate of t(8;21) AML in children is about 30% 
and long-term survival rate is about 75% which indicate 
the need for improved therapeutic strategies [14–18]. 
Although molecular analysis such as next-generation 
sequencing and transcriptome analysis have revealed many 
previously unknown recurrent mutations and additional 
mechanistic insights such as alternations in the epigenetic 
status, still the results as well as the prediction of drug 
response to treatments with specific newly designed 
inhibitors in AML are missing. Single kinase inhibitor 
therapy can default when cancer cells bypass through 
alternative routes, adaptation in redundancy, and escape 
mechanism [19–20]. Deregulated protein phosphorylation 
by aberrant protein kinase activity is frequently observed 
in cancer, e.g. leukemia [20]. Aberrant expression of 
multiple signal transduction pathways is associated 
with a worse prognosis [21]. In order to circumvent the 
constraints of a certain kinase inhibitor, it is desirable to 
elucidate signaling networks to identify suitable targets 
that are essential in leukemic cell proliferation and 
survival to develop the most successful combination 
therapy approach for AML-specific subgroups. Therefore, 
we performed peptide microarray profiling array as we 
did previously [20, 22] for t(8;21) AML and found that 
phospholipase C-gamma 1 (PLC-γ1) at tyrosine 783 was 
highly phosphorylated in these leukemia cells.
PLC-γ1 can be phosphorylated at tyrosine residues 
(Y783, Y771) and also at a serine residue (S1248). Among 
these residues, PLC-γ1_Y783 is known to be a critical 
phosphorylation site for PLC-γ1 enzymatic activation 
whereas PLC-γ1_S1248 negatively regulates PLC-γ1 
activity [23, 24]. PLC-γ1 is a key signaling molecule 
that hydrolyzes phosphatidylinositol-4,5-biophosphate 
to generate inositol-1,4,5-triophosphate (IP3) and 
1,2-diacylglycerol (DAG), which in turn, activate 
intracellular Ca2+ and protein kinase C (PKC) signaling 
pathways [25]. PLC-γ1 is activated by binding to tyrosine 
kinases and subsequent phosphorylation and transduces 
signals to the downstream PKC–RAF–MEK–MAPK 
pathway. These pathways are known for their enhancement 
of cell proliferation, cell migration and cell survival when 
activated. Specifically, PLC-γ1 plays a critical role in 
vascular endothelial growth factor (VEGF) mediating 
signaling in endothelial cells. Interestingly, aberrant VEGF 
signaling promotes autocrine AML blast cell proliferation, 
survival, and chemotherapy resistance [26]. PLC-γ1 
activity is regulated by PI3K through the interaction of 
the PI3K product PIP3, and PLC-γ1 PH domain. The 
role of PLC-γ1 in cancer progression specifically in 
carcinomas were extensively studied [27–29]. Its role, if 
any, in AML progression is not studied yet. Markova B, 
et al. underscored the possible importance of PLC-γ1 in 
chronic myeloid leukemia (CML) leukemogenesis via a 
novel Akt-independent, PLC-γ1-driven mechanism of 
activation of mTOR/p70S6-K in BCR-ABL-positive cells 
[30]. Together, further studies to investigate the role of 
PLC-γ1 in other types of leukemia are necessary.
In this study, we aimed to study the functional 
role of PLC-γ1 in t(8;21) AML and its interference with 
signaling networks. Briefly, we identified the higher 
PLC-γ1 expression in t(8;21) AML patients and we 
studied the effects of loss of PLC-γ1 in kasumi-1 and gene 
expression profiles using shRNA-mediated suppression. In 
addition, the chemosensitivity of PLC-γ1 suppressed cells 
was evaluated.
RESULTS
Peptide microarray profiling identifies PLC-γ1 
as a potentially druggable target for t(8;21) 
leukemia
Phospholipase C-gamma 1 (PLC-γ1_Y783) was 
identified from our previous peptide array (unpublished 
data) as one of the highest phosphorylated peptides in 
t(8;21) AML samples when compared to NBM or CN-
AML (Figure 1A). It is known that phosphorylation of 
PLC-γ1 at Y783 increases the PLC-γ1 enzymatic activity 
and PLC-γ1 phosphorylation at S1248 inhibits the PLC-γ1 
enzymatic activity. From our data, it could be appreciated 
that phosphorylation status of PLC-γ1_Y783 was vice 
versa to the phosphorylation of PLC-γ1_S1248 in t(8;21) 
AML (p<0.05 and p<0.01, Figure 1A and p<0.05, p<0.01, 
Figure 1B). About 38% (5/13) t(8;21) samples had c-KIT 
mutations and no significant difference of PLC-γ1_Y783 
phosphorylation level was found between the t(8;21) 
samples with or without KIT mutation (data not shown). 
The expression profile of PLC-γ1 in a publicly available 
pediatric AML database (http://r2.amc.nl) also showed 
significant highest expression of PLC-γ1 in t(8;21) AML 
when compared to other AML karyotypes (p<0.001, 
Figure 1C). Since the role of PLC-γ1 is currently unknown 
in t(8;21) AML, we aim to study the functional role of 
PLC-γ1 in t(8;21) AML using kasumi-1 cell line by 
studying its effect on cellular growth and survival and 
underline mechanisms.
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PLC-γ1 is highly expressed in primary 
t(8;21) AML samples and AML cell lines. 
Downregulation of core RUNX1/ETO (AML1-
ETO) in kasumi-1 cells reduced PLC-γ1 
expression
We checked the protein expression PLC-γ1 (both 
phospho and total PLC-γ1) by western blot analysis 
in different AML cell lines and primary AML samples 
to confirm PLC-γ1 peptide phosphorylation data from 
the peptide microarray (Figure 2A). PLC-γ1 expression 
of both total-PLC-γ1 and phospho-PLC-γ1 were 
found in AML primary samples among them t(8;21) 
AML samples showed the highest protein expression. 
Similarly, kasumi-1 cells and t(8;21) AML showed the 
highest level of phospho-PLC-γ1 and total-PLC-γ1 
expression among others. Furthermore, we used the RNA 
interference approach of AML1-ETO (shAE) for the 
elucidation of the dependency of PLC-γ1 expression in 
the t(8;21)-positive AML kasumi-1 cell line (Figure 2B, 
2C). Figure 2B showed clearly less AML1-ETO protein 
expression compared to control plasmid. The expression 
of PLC-γ1 was reduced overtime after transduction with 
shAE compared with control (Figure 2C). Furthermore, 
we checked if the consensus sequence of AML1-ETO 
(TGTGGT) could be found in any region of the PLC-γ1 
gene by sequence matching. AML1-ETO consensus 
sequence is present in (-) 4081 base pairs upstream of 
transcription start site (TSS) of the PLC-γ1 which could 
be a regulatory region of PLC-γ1 (data not shown).
Suppression of PLC-γ1 in kasumi-1 cells inhibit 
cell growth, induced apoptosis and cell cycle 
arrest
The design of shPLC-γ1construct is shown in the 
Figure 3A. Two different lentiviral vectors were used: 
shPLC-γ1 that targeted the PLC-γ1 mRNA; and shSCR 
encoded for a nonspecific scrambled (SCR) shRNA. Two 
shPLC-γ1 constructs (PLC-γ1-A and PLC-γ1-B) were 
prepared for the transduction. The shPLC-γ1 expressing 
cells showed ~35% (PLC-γ1-A) and ~60% (PLC-γ1-B) 
decrease in PLC-γ1 mRNA level compared with the 
control (p<0.05 and P<0.001, Figure 3B). These results 
were confirmed by PLC-γ1 protein level analysis by 
western blotting (Figure 3C). The shRNA-mediated 
silencing of PLC-γ1 leads to significant suppression of the 
kasumi-1 cell growth after day 8 of transduction (p<0.05, 
Figure 3D).
Downregulation of PLC-γ1 in kasumi-1 cells 
induced apoptosis and cell cycle arrest
To elucidate the nature of the cell growth 
suppression, we measured an impact of PLC-γ1 
downregulation on the apoptosis. The percentage 
of Annexin V-positive kasumi-1 cells of PLC-γ1-B 
transduced cells was significantly higher than in shSCR-
expressing cells (p<0.01, Figure 4A). Thus, the proof of 
principal results strongly supports that PLC-γ1 might 
be important in t(8;21) AML survival as suppression of 
PLC-γ1 inhibited cell growth and induced apoptosis in 
kasumi-1 cells. To explain the dramatic effect of PLC-γ1 
knockdown on cell growth, we studied the consequences 
of PLC-γ1 knockdown on cell cycle progression. We 
hypothesized that the phenotypic effects of growth 
inhibition and the induction of apoptosis could be assigned 
to a defect in cell cycle regulation. Cell cycle analysis of 
PLC-γ1 knockdown cells revealed a significant increase 
of the percentage of cells in G0 /G1 phase (p<0.05 and 
p<0.001) of cell cycle, significantly decrease in S-phase 
and G2/M (p<0.05, p<0.01 and p<0.001) suggesting G0/
G1 phase cell cycle arrest (Figure 4B). The exact changes 
of cell cycle phases are also shown with the original dot 
plot from the FACS analysis (Supplementary Figure 1). 
To understand the signal transduction that could explain 
PLC-γ1 knockdown mediated cell death in kasumi-1 cell, 
we analyzed proteins involved in apoptosis and cell cycle 
Figure 1: Higher PLC-γ1 peptide phosphorylation in t(8;21) AML. Dot plot of mean peptide intensity of PLC-γ1 peptides were 
compared between t(8;21) AML (n=13) compared to CN-AML (n=17) or NBM (n=4). (A) Phosphorylation of PLC-γ1 at tyrosine residue 
783 was significantly highly phosphorylated in t(8;21) AML compared to CN-AML or NBM. (B) Phosphorylation of PLC-γ1 at serine 
residue 1248 was significantly lowly phosphorylated in t(8;21) AML compared to CN-AML or NBM. (C) Gene expression of PLC-γ1 
among different AML karyotypes from a publicly available pediatric AML gene array data set, showed that PLC-γ1 was significantly highly 
expressed in t(8;21) AML.
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Figure 2: PLC-γ1 expression in AML cell lines, primary AML samples, and AML1-ETO suppressed kaumi-1 cells. 
(A) Western blot analysis confirms the higher PLC-γ1 expression in kasumi-1 cells compared to other cell lines (OCI-AML3, ME-1 and 
THP-1). Similarly, higher PLC-γ1 expression (both phospho-PLC-γ1 at Y783 and total PLC-γ1 protein) was found in t(8;21) AML primary 
samples (n=3) compared to other primary AML (CN-AML, inv16 and MLL-rearranged AML). (B) shRNA of AML1-ETO (RUNX1/ETO) 
in kasumi-1 cells, confirmed the AML1-ETO suppression in a day dependent manner by Western blot analysis. (C) Downregulation of 
PLC-γ1 protein was observed in suppressed AML1-ETO kasumi-1 cells in a day dependent manner by western blot analysis
Figure 3: PLC-γ1 is essential for kasumi-1 cell growth. (A) Schematic diagram for generating the shRNA construct for PLC-γ1. 
(B) Two shRNAs of PLC-γ1 were used (named as; PLC-γ1-A and PLC-γ1-B). PLC-γ1 was successfully downregulated in kasumi-1 cells 
which was confirmed by RT-PCR. (C) Quantification of PLC-γ1 at the protein level in transduced kasumi-1 cells by western blot confirming 
the PLC-γ1 downregulation. (D) Growth curve analysis shows that PLC-γ1 downregulation results in a decrease cell growth in kasumi-1 
cells (n=4). * denoted the comparison between SCR vs PLC-γ1_A; # denoted the comparison between SCR vs PLC-γ1_B and $ denoted 
the comparison between PLC-γ1_A vs PLC-γ1_B.
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regulation. Immunoblot analysis showed an induction 
of pro-apoptotic BAXa/b and a slight downregulation 
of anti-apoptotic Bcl-2 in PLC-γ1 transduced cells 
(Figure 4C). Simultaneously, to gain more insights into 
the observed cell-cycle regulation, we found significant 
increase in p-Chk2 by PLC-γ1 knockdown of kasumi-1 
cells (Figure 4C). The quantification of the western blot 
analysis is presented as Supplementary Figure 2. These 
data implicates that PLC-γ1 knockdown may induce 
apoptosis and increase G0/G1 cell-cycle arrest with the 
decrease S-phase and G2/M phase in kasumi-1 cells by 
enhancing p53 DNA binding that prevents the AML cells 
from entering mitosis and finally results in apoptosis.
Gene expression profiling of PLC-γ1 knockdown 
cells
To understand the changes of transcriptional 
consequences of the PLC-γ1 knockdown in kasumi-1 
cell, we performed the gene expression microarray 
profiling; using the transduced kasumi-1 cells of SCR, 
shPLC-γ1-A and shPLC-γ1-B. Since we observed strong 
phenotypes of growth inhibition, apoptosis induction and 
cell cycle arrest upon PLC-γ1 knockdown, therefore, we 
made an overview of interesting genes that were either 
up- or downregulated in PLC-γ1 (Table 1). The mRNA 
microarray data confirmed that a list of genes related to 
apoptosis (BAX, BCL2L12, PRKCD, STAT3, CASP8, 
APAF1) and DNA damage response (ATM, RAD9, 
BARD1, XRCC5, EXO1, RBL2, ERBB3, MAPK14) were 
upregulated in shPLC-γ1 samples whereas genes related 
to cell growth (BID, IKBKB, NFKB1), proliferation or 
differentiation (eIF2S1, CDKN2B, PKCH, GFAP, ID1, 
PRDM1, p120GAP, ARHGEF10) were downregulated 
in this shPLC-γ1 samples. Interestingly, we observed 
downregulation of two important calcium signaling 
regulatory genes CAMK2B and RYR1 which are known 
to be downstream of PLC-γ1 signaling.
Functional importance of PLC-γ1 in kasumi-1 
cells under stress conditions (chemotherapeutic 
drugs and hypoxia)
To examine if PLC-γ1 suppression has effects on 
chemotherapeutic drugs, therefore, we evaluated the effect 
of chemo-sensitivity of PLC-γ1 suppressed kasumi-1 
cells. PLC-γ1 knockdown cells at day 4 after transduction 
were shown to induce significant cellular sensitivity to 
the genotoxic agents; mitoxantrone (p<0.05, p<0.001), 
amsacrine (p<0.01, p<0.001) and etoposide (p<0.05, 
p<0.01 and p<0.001) in kasumi-1 in a dose-dependent 
manner (Figure 5A–5C). Additionally, we evaluated the 
cell growth of PLC-γ1 knockdown cells under another 
stress condition, hypoxia. The cells were kept under 
hypoxia condition for 48h. Cell count analysis revealed 
a significant decreased in cell number in PLC-γ1-B 
construct compared to SCR in hypoxic condition (p<0.05, 
Figure 5D).
DISCUSSION
AML is a life threatening malignancy in children. 
The t(8;21) (q22;q22) chromosomal translocation is one of 
the most frequent genetic alterations in AML. About 30% 
Figure 4: PLC-γ1 downregulation induces apoptosis and cell cycle arrest in kasumi-1 cells. (A) Percentage of apoptosis 
(Annexin V-positive) at day 4 after transduction (n=4) shows an increase apoptotic cell number for PLC-γ1 downregulated cells (PLC-
γ1-B construct only) as compared to control transduced cells. (B) Cell cycle analysis shows a reduction in the percentage of cells in S and 
G2/M phases with a concomitant increase of cells in G0/G1 phases in PLC-γ1 downregulated cells in comparison with control shRNA 
(SCR). * denoted the comparison between SCR vs PLC-γ1_A; # denoted the comparison between SCR vs PLC-γ1_B and $ denoted the 
comparison between PLC-γ1_A vs PLC-γ1_B. (C) Immunoblot analysis confirms the significant increase of pro-apoptotic BAX protein and 
phosphorylation of chk2 protein in PLC-γ1 downregulated cells compared to SCR.
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t(8;21) AML patients undergo relapse which indicates 
the need for improved therapeutic strategies [14–18]. 
Therefore, the development of new therapeutic strategies 
for t(8;21) AML is necessary. We identified PLC-γ1 
as a potential target for t(8;21) AML from our peptide 
microarray profiling. PLC-γ1 is known to play a role in 
the progression of several carcinomas by activating PI3K/
AKT/mTOR and MAPK pathways which regulate cell 
proliferation and survival [27–29, 31]. The knowledge 
about the role of PLC-γ1 in leukemia progression is very 
limited. Only one study showed that in CML, PLC-γ1 
involved in leukemogenesis via a novel Akt-independent, 
PLC-γ1-driven mechanism of activation of mTOR/
p70S6-K [30]. Therefore, it is important to investigate 
whether PLC-γ1 contributes in the regulation of t(8;21) 
AML.
Table 1: List of up- and downregulated genes in both shPLC-γ1-A and shPLC-γ1-B versus shSCR transduced cells
Upregulated genes in PLC-γ1 KD cells Down regulated genes in PLC-γ1 KD cells
Apoptosis related genes Genes involved in Cell growth and survival
BAX (BCL2-associated X protein) BID (BH3 interacting domain death agonist)
BCL2L12 (BCL2 Like 1)
IKBKB(Inhibitor of Kappa light polypeptide gene 
enhanceriIn B-Cells, kinase Beta)
PRKCD (Protein Kinase C Delta) NFKB1(Nuclear Factor Kappa B Subunit 1)
STAT3(Signal Transducer And Activator Of Transcription 3) Genes involved in Cell proliferation and differentiation:
CASP8(Caspase 8)
eIF2S1(Eukaryotic Translation Initiation Factor 2 Subunit 
Alpha)
APAF1 (Apoptotic protease activating factor 1) CDKN2B(Cyclin Dependent Kinase Inhibitor 2B)
DNA damage and cell cycle regulated genes PKCH(Protein Kinase C Eta)
ATM(Ataxia Telangiectasia Mutated)
GFAP Glial Fibrillary Acidic Protein (Glial Fibrillary 
Acidic Protein)
RAD9(RAD9 Checkpoint Clamp Component B) ID1 (Inhibitor Of DNA Binding 1, HLH Protein)
BARD1(BRCA1 Associated RING Domain 1) PRDM1(PR/SET Domain 1)
XRCC5(X-Ray Repair Cross Complementing 5) p120GAP (RAS P21 Protein Activator 1)
EXO1(Exonuclease 1)
ARHGEF10 (Rho Guanine Nucleotide Exchange Factor 
10)
RBL2(RB Transcriptional Corepressor Like 2) Genes involved in Calcium signaling:
ERBB3(Erb-B2 Receptor Tyrosine Kinase 3)
CAMK2B (Calcium/Calmodulin Dependent Protein Kinase 
II Beta)
MAPK14(Mitogen-Activated Protein Kinase 14) RYR1 (Ryanodine receptor 1)
Figure 5: Functional importance of PLC-γ1 in kasumi-1 cells under stress conditions (chemotherapeutic drugs and 
hypoxia). (A-C) PLC-γ1 knockdown cells at day 4 after transduction were shown to significantly induce cellular sensitivity to the genotoxic 
agents; mitoxantrone (p<0.05, p<0.001), amsacrine (p<0.01, p<0.001) and etoposide (p<0.05, p<0.01 and p<0.001) in kasumi-1 in a dose-
dependent manner. (D) Cell viability was found to be reduced in all three conditions upon 48h hypoxic condition (Hyp-48h). Kasumi cells 
with PLC-γ1_B shRNA was significantly reduced (p<0.05) compared to scramble (SCR). * denoted the comparison between PLC-γ1_B vs 
SCR or PLC-γ1_A or in normoxic condition and # denoted the comparison between PLC-γ1_B vs SCR or PLC-γ1_A in hypoxic condition.
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In this study, we described a novel role of PLC-γ1 
in t(8;21) AML. At first, we found higher peptide 
phosphorylation of PLC-γ1 at a tyrosine residue Y783 
relative to NBM and CN-AML which was opposite 
to PLC-γ1 serine residue (S1248). PLC-γ1_Y783 is 
known to be a critical phosphorylation site for PLC-γ1 
enzymatic activation whereas PLC-γ1_S1248 negatively 
regulates PLC-γ1 activity [23, 24]. The PLC-γ1 peptide 
phosphorylation was confirmed at protein levels both 
phosphorylation and total protein of PLC-γ1 in primary 
t(8;21) AML samples and kasumi-1 cells compared to 
other karyotypes and cell lines. Publicly available gene 
expression data of PLC-γ1 confirmed the higher expression 
of PLC-γ1 in t(8;21) AML. In addition, we also observed 
suppression of PLC-γ1 in AML1–ETO knock down 
kasumi-1 cells which indicated PLC-γ1 downregulation 
upon AML1-ETO suppression that might induce more 
kasumi-1 cell death. In previous studies, AML1-ETO 
was considered to be the most attractive target for the 
specific suppression of the t(8;21) translocation positive 
tumors although the effectiveness of this therapy remains 
unclear [7, 12]. So far no evidence has been published that 
PLC-γ1 could be a direct target for AML1-ETO. Based 
on the sequence matching analysis, we found that AML1-
ETO consensus sequence is present in (-) 4081 base pairs 
upstream of transcription start site (TSS) which could be 
a regulatory region of PLC-γ1. Therefore, further study is 
needed to investigate in details.
Secondly, we investigated the shRNA-mediated 
inhibition of PLC-γ1 as currently available PLC-γ1 
inhibitor U73122 is very unspecific [32]. PLC-γ1 
knockdown in kasumi-1 cells resulted in repression 
of cell proliferation and more importantly, enhanced 
apoptosis which appeared to be the net results of the 
changes in the cell cycle. Immunoblot analysis confirmed 
the alternation of apoptosis and cell cycle regulation. 
Furthermore, we performed gene expression profiling 
to elucidate the phenotypic effects observed in response 
to shRNA mediated PLC-γ1 knockdown. Briefly, we 
observed up-regulation of apoptotic and DNA damage 
response genes together with the down regulation of cell 
growth, proliferation and differentiation genes, consistent 
with the observed phenotypic effects. Importantly, genes 
involve in Ca2+ signaling (CAMK2B and RYR1) were 
also downregulated in PLC-γ1 knockdown cells which 
are known to be altered via PLC-γ1 [33, 34]. Thus, the 
observed alternations of these genes in response to shRNA 
mediated PLC-γ1 knockdown contributes to the strong 
phenotypic effects found in our data.
At the end, we evaluated the effect of chemo-
sensitivity of PLC-γ1 suppressed kasumi-1 cells. We found 
that PLC-γ1 knockdown cells were shown to have a higher 
cellular sensitivity to the genotoxic agent mitoxantrone, 
amsacrine and etoposide which indicated a possible future 
scope of synergistic effect of chemotherapeutics drugs 
together with PLC-γ1 inhibition although PLC-γ1 specific 
inhibitor needs to be developed at first. Similar approaches 
have been successfully used in different studies [34–37]. 
In addition, hypoxic stress showed less cell growth upon 
PLC-γ1 suppression.
In conclusion, we demonstrated higher PLC-γ1 
phosphorylation and expression in t(8;21) AML. 
Moreover, our in vitro findings suggest an important 
role of PLC-γ1 in the survival of t(8;21) AML. Thus, 
PLC-γ1 may have important function in t(8;21) AML 
leukemogenesis. Therefore, these results emphasize the 
need for future investigation validating the role of PLC-γ1 
as potential therapeutic targets for t(8;21) AML and it 
showed a possibility to use a combination therapy of anti 
AML1-ETO with anti PLC-γ1 for t(8;21) AML.
MATERIALS AND METHODS
AML patient samples and peptide microarray
Primary blood or bone marrow samples of newly 
diagnosed pediatric AML patients of t(8;21) AML (n=13), 
cytogenetically normal (CN-AML) (n=17) and bone 
marrow from healthy control (n=4) were collected after 
obtaining written informed consent in accordance with 
the declaration of Helsinki and the study was approved 
by the Medical Ethical Committee of the University 
Medical Center Groningen (UMCG). The associated 
patient characteristics of AML patients are described in 
Supplementary Table 1. Briefly, mononuclear cells were 
separated by lymphoprep density gradient (Nycomed, 
Oslo, Norway), and cryopreserved in liquid nitrogen 
until use. The cryopreserved leukemia cells were thawed 
rapidly at 37°C and diluted in a 6 ml volume of newborn 
calf serum, as described previously [20]. The remaining 
blast cell population contained >95% leukemia cells with 
PI staining, as shown in our previous study and is referred 
to hereafter as leukemia cells [20]. Previously, we used 
a high-throughput PepChipTM Kinomics microarray 
system (Pepscan, Lelystad, The Netherlands) to determine 
the peptide phosphorylation profiles of AML samples 
as described previously [20, 22]. This array contains 
976 different kinase peptide substrates, each spotted as 
triplicates. The protein-derived peptide sequences contain 
phosphorylation sites that can be used as substrates for 
kinases active in the samples. The assay readout is the net 
sum of phosphorylation at each peptide, whether acted on 
by one kinase, or several different kinases.
AML cell lines
OCI AML3, Kasumi-1, ME-1 and THP-1 cell lines 
are obtained from American Type Culture Collection 
(ATCC) (Manassas, VA, USA). Kasumi-1 is characterized 
by a t(8;21) chromosome translocation. This translocation 
juxtaposes the AML1 with ETO (or MTG8) gene, giving 
rise to the fusion gene AML1-ETO. All cell lines are 
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cultured in RPMI-1640 medium supplemented with 1% 
penicillin/streptomycin and 10-20% fetal calf serum 
(Bodinco, Alkmaar, The Netherlands).
shRNA-mediated knockdown
Lentiviral vector (pLKO.1) containing shRNA 
sequences targeting PLC-γ1 were obtained from Open 
Biosystems (Waltham, MA, USA) and genetically 
modified into a pLKO1-mCherry vector. Sequences are 
available upon request. Lentiviral particles were generated 
by co-transfection of the pLKO1-mCherry-shPLC-γ1 or 
scrambled vector (SCR) with packaging plasmid psPAX2 
and the envelope plasmid pMD2.G into 293T cells using 
FuGENE HD transfection reagent (Roche, Woerden, The 
Netherlands) as described previously [38]. Kasumi-1 
cells were incubated with lentiviral supernatants for two 
consecutive days after which stably transduced cells were 
expanded. The mCherry expression was measured to 
determine transduction efficiency by flow cytometry and 
the downregulation of PLC-γ1 was confirmed by RT-PCR 
and Western blot analysis. Subsequently, transduced cells 
were cultured and the rate cell proliferation was measured 
by absolute cell counting at every 48h using a Coulter 
Counter (Beckman Coulter, Fullerton, CA, USA) to assess 
cell growth in a time-dependent manner. The sequence 
of the AML1/MTG8 siRNA was previously described 
[39]. The lentiviral transgene plasmids pdc-SEW, AML1/
MTG8- and shRNA-controls were cloned as described 
[40]. Lentiviral constructs encompassing the shRNAs 
encode GFP (green fluorescent protein) as a reporter gene. 
The preparation of recombinant lentiviral supernatants 
and lentiviral transductions were performed as described 
earlier [41]. Then transduced cells were cultured and cell 
pellets were made to confirm AML1-ETO knockdown and 
to check the PLC-γ1 protein expression at different days 
of transduction.
Quantitative real-time PCR (qRT-PCR) and 
western blot analysis
The mRNA and protein expression of PLC-γ1 were 
assessed by quantitative real-time PCR (qRT-PCR) and 
western blot analysis respectively. Briefly, for qRT-PCR, 
total RNA was isolated (RNeasy mini kit, Qiagen, Hilden, 
Germany) and subsequent complementary DNA was 
synthesized from 1 μg RNA (First Strand cDNA Synthesis 
kit, Thermo Scientific, Waltham, MA, USA) according 
to manufacturer’s protocol. To check the knockdown 
PLC-γ1 mRNA expression was detected in triplicate using 
SYBR Green qRT-PCR (Applied Biosystems, Darmstadt, 
Germany) and normalized to RPL22 as a reference gene 
[42]. Relative mRNA expression level of the PLC-γ1 was 
calculated using the 2–ΔΔCT method relatively to SCR 
transduced cells.
For western blot, 1x106 cells of newly diagnosed 
primary AML samples, cell lines, and PLC-γ1 transduced 
cells were lysed in laemmli sample buffer (Bio-Rad 
Laboratories, Veenendaal, The Netherlands). Proteins were 
separated by SDS-polyacrylamide gel electrophoresis and 
transported to nitrocellulose membranes as described 
previously [38]. First, the membranes were incubated 
overnight with primary antibodies for PLC-γ1, p-PLC-γ1, 
AML1, Bcl2, BAX, p-Chk2, p-p53 (Cell signalling, 
Danvers, MA, USA), t-p53 (BD Biosciences), t-Chk1, 
t-Chk2 (Santa Cruz) and GAPDH (Fitzgerald Inc.) 
followed by 1h incubation with HRP-conjugated 
secondary antibodies (DAKO Cytomation). Protein bands 
were visualized by chemiluminescence, using ChemiDoc 
MP system (Bio-rad laboratories) and normalized using 
GAPDH.
Flow cytometry for apoptosis, cell proliferation, 
and cell cycle analysis
For apoptosis analysis upon PLC-γ1 knockdown, 
transduced cells were stained with Annexin V-FITC 
(Annexin-V-FLUOS Staining Kit, Roche) (1ml staining 
buffer, with the addition of 20μl Annexin V-FITC) as 
described previously [43]. For cell proliferation and 
cell cycle analysis, transduced cells were incubated 
with BrdU (5-bromo-20 -deoxyuridine) for 4 hours 
at 37°C after which the cells were fixed, denaturated, 
and stained with anti-BrdU Rabbit anti-Mouse FITC–
conjugated secondary antibody (Dako cytomation) for 30 
min at room temperature in the dark and then cells were 
stained with propidium iodide (PI) (Roche, Woerden, the 
Netherlands) for an additional 15 minutes in the dark at 
37°C as described previously [43, 44]. All flow cytometry 
experiments were performed on a LSR-II flow cytometer 
(BD FACS DIVA software, BD bioscience, Breda, The 
Netherlands) and analyzed using FlowJo software (Tree 
Star Inc., Ashland, OR, USA). The cell cycle distribution 
was determined by flow cytometry for DNA content. 
Results were presented as a percentage of kasumi-1 cells 
(transduced with PLC-γ1 or with SCR) in each phase of 
cell cycle in relation to a total number of cells counted.
Induction of hypoxia
For induction of hypoxia, shPLC-γ1 and shSCR 
transduced kasumi-1 cells were kept in an air tight with 
a pouch (Gaspak, Becton Dickinson) without oxygen for 
48h at 37°C as described previously [45]. The rate cell 
proliferation was measured by absolute cell counting 
after 48h using a Coulter Counter (Beckman Coulter, 
Fullerton, CA, USA) to assess cell growth under hypoxia 
and normoxia.
Chemo-sensitivity and cell viability assay
Quantification of Kasumi-1 cell viability (SCR vs 
shPLC-γ1) was carried out using WST-1 assays with and 
without chemotherapeutic drugs as described previously 
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[20]. These assays were performed in sextuple according 
to manufacturer’s protocol (Roche). Cells were seeded at 
a density of 0.1–1x105 cells per 100 μl/well in a 96 wells 
plate in RPMI medium supplemented with 1% fetal calf 
serum with and without chemotherapeutic drugs (range 
of concentration), mitoxantrone (0.1-1 μM, Sandoz BV, 
The Netherlands), amsacrine (0.25-1 μg/mL, ProStrakan 
Pharma, The Netherlands) and etoposide (2.5-10 μM, 
Pharmachemie BV, The Netherlands). The mitochondrial 
activity of AML cell was measured after 48 h using 
a microplate reader at 450 nm (Benchmark; Bio-Rad 
Laboratories). Cell survival percentages (viability) are 
determined relative to non-treated cells.
Gene expression and pathway analysis
Total RNA was isolated from transduced kasumi-1 
cells of scrambled and shPLC-γ1 with the RNeasy mini 
kit. Further processing including the quality control, RNA 
labeling, hybridization, and data extraction was performed 
at ServiceXS B.V. (Leiden, The Netherlands) using 
Illumina HumanHT-12 v4.0 Expression BeadChips as 
previously described [38]. Briefly, scans (Illumina iScan), 
image analysis and extraction of raw data (Illumina 
GenomeStudio v2011.1) were done by ServiceXS B.V. 
Then, we performed quantile normalization, log2-
transformation, and group comparisons. Furthermore, 
a system biology pathway analysis tool, MetaCoreTM 
(GeneGo Inc., St Joseph, MI, USA), was used to explore 
the signaling pathways between scrambled and shPLC-γ1 
kasumi-1 cells.
Statistical analysis
The comparison of patient characteristics between 
t(8;21) AML and CN-AML were assessed in SPSS 
(Statistical Package for the Social Sciences). Mann-
Whitney U test (for continuous variables) and Pearson 
Chi-Square test (for categorical variables) were used 
to assess the difference between these two groups of 
patients. Other data were expressed as means+SEM unless 
described differently. Comparisons between groups were 
made using non-parametric tests (Mann–Whitney U) and 
the parametric paired and unpaired two-tailed t-test, a 
P-value less than 0.05 (alpha) was considered to denote 
statistically significant difference.
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